Was the Privia Health (PRVA) CEO’s share sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states that the reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, indicating the transactions were pre-arranged rather than timed discretionarily around short-term market movements.

Privia Health (PRVA) CEO gets stock awards, sells shares under plan

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Privia Health Group Chief Executive Officer Parth Mehrotra reported a mix of stock awards and a planned share sale. He received 171,904 shares of common stock as a grant or award on March 11, 2026, and 141,342 shares as a grant or award on March 10, 2026, both at no cash cost to him.

On March 10, 2026, he sold 21,097 shares of common stock at a weighted average price of $22.71 per share, with individual trade prices ranging from $22.27 to $23.23, under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly held 635,944 shares of Privia Health Group common stock.

Insider Trade Summary 10b5-1

Net Seller: 21,097 shares ($479,113)

Net Sell 3 txns

Insider Mehrotra Parth

Role Chief Executive Officer

Sold 21,097 shs ($479K)

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $0.01 par value per share	171,904	$0.00	--
Sale	Common Stock, $0.01 par value per share	21,097	$22.71	$479K
Grant/Award	Common Stock, $0.01 par value per share	141,342	$0.00	--

Holdings After Transaction: Common Stock, $0.01 par value per share — 635,944 shares (Direct)

Footnotes (1)

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person . The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.27 to $23.23 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Reflects restricted stock units under the 2021 Omnibus Incentive Plan that will vest in substantially equal annual installments on the first, second and third anniversaries of the grant date, generally subject to continued service throughout such dates. Vesting and distribution to reporting person of 141,948 shares underlying performance stock units that were granted on May 9, 2023, and 29,956 shares underlying performance stock units that were granted on July 1, 2023, in both cases for the performance period 2023-2025.

Form 4 Insider Transactions: What Each Field Means →

03/12/2026 - 05:47 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mehrotra Parth

(Last)

(First)

(Middle)

PRIVIA HEALTH GROUP, INC.

950 N. GLEBE RD., SUITE 700

(Street)

ARLINGTON

22203

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Privia Health Group, Inc. [ PRVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $0.01 par value per share	03/10/2026		S⁽¹⁾		21,097	D	$22.71⁽²⁾	322,698	D
Common Stock, $0.01 par value per share	03/10/2026		A		141,342⁽³⁾	A	$0	464,040	D
Common Stock, $0.01 par value per share	03/11/2026		A		171,904⁽⁴⁾	A	$0	635,944	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person .

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.27 to $23.23 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

3. Reflects restricted stock units under the 2021 Omnibus Incentive Plan that will vest in substantially equal annual installments on the first, second and third anniversaries of the grant date, generally subject to continued service throughout such dates.

4. Vesting and distribution to reporting person of 141,948 shares underlying performance stock units that were granted on May 9, 2023, and 29,956 shares underlying performance stock units that were granted on July 1, 2023, in both cases for the performance period 2023-2025.

Remarks:

	/s/ Anita Beth Adams, as attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Privia Health (PRVA) CEO Parth Mehrotra report?

Parth Mehrotra reported two stock awards and one share sale. He received grants totaling 171,904 shares on March 11, 2026 and 141,342 shares on March 10, 2026, and sold 21,097 shares in an open-market transaction.

How many Privia Health (PRVA) shares did the CEO sell and at what price?

He sold 21,097 shares of Privia Health common stock. The weighted average sale price was $22.71 per share, with individual trades executed between $22.27 and $23.23, as disclosed in the Form 4 footnotes.

What stock awards did the Privia Health (PRVA) CEO receive in this Form 4?

He received 171,904 shares and 141,342 shares of common stock as grant or award acquisitions. These include restricted stock units and performance stock units that vest over time under the company’s 2021 Omnibus Incentive Plan, subject to continued service and performance conditions.

How many Privia Health (PRVA) shares does CEO Parth Mehrotra hold after these transactions?

Following the reported grants and sale, he directly holds 635,944 shares of Privia Health Group common stock. This total reflects the net position after receiving stock awards and completing the 21,097-share open-market sale disclosed in the filing.

What vesting terms apply to the Privia Health (PRVA) CEO’s new equity awards?

The filing explains that certain restricted stock units vest in substantially equal annual installments over three years, generally contingent on continued service, while performance stock units vest and distribute shares based on performance for the 2023–2025 period, as described in the footnotes.